Current investments

Receive information about upcoming investment opportunities

Sign up below to get information about upcoming investment opportunities and investor lunch meetings with the companies’ managements.

Completed investments

The Sciety syndicate invests in Synartro Synartro is developing a novel therapy for knee osteoarthritis.

Synartro

Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.

Read more

Cavis Technologies

Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.

Read more
Sciety_invests_in_Elypta

Elypta

Elypta has developed a new method for early cancer diagnosis. Liquid Biopsy is a rapidly growing field that is expected to be of great importance for cancer diagnosis.

Read more

Athera Biotechnologies

The company is in Phase II with a pharmaceutical candidate for a life-threatening illness for which there are currently no sufficient therapies.

Read more

Exits

Liv Diagnostics

Tumor cell proliferation causes 90% of all cancer deaths. Liv Diagnostics is developing new technology to measure the spreading capacity of tumor cells and provide predictive information on the risk of metastasis.

Read more